08:00 , Jan 5, 2004 |  BC Week In Review  |  Company News

Barr Laboratories Inc., Galen deal

The companies said they have received a letter from the Federal Trade Commission requesting information concerning BRL's proposed acquisition from GAL of U.S. and Canadian rights to Loestrin and Loestrin FE oral contraceptives. The FTC...
07:00 , Sep 15, 2003 |  BC Week In Review  |  Company News

Barr Laboratories Inc., Galen deal

BRL signed a letter of intent to acquire from GAL exclusive rights in the U.S. and Canada to Loestrin and Loestrin FE oral contraceptives. The companies also proposed to settle their pending litigation related to...
07:00 , Sep 11, 2003 |  BC Extra  |  Company News

Barr, Galen contraceptive deals

BRL signed a letter of intent to acquire exclusive rights from Galen (LSE:GAL; GALN) to Loestrin and Loestrin FE oral contraceptives in the U.S. and Canada. The companies also proposed to settle their pending litigation...
07:00 , Apr 21, 2003 |  BC Week In Review  |  Company News

Galen, Pfizer deal

GAL completed its acquisition of femhrt hormone replacement therapy from PFE. The deal completes GAL's $359 million acquisition of a women's healthcare portfolio from PFE that also included Estrostep and Loestrin oral contraceptives (see BioCentury,...
08:00 , Mar 31, 2003 |  BC Week In Review  |  Company News

Galen, Pfizer deal

GAL completed its previously announced purchase of Estrostep and Loestrin oral contraceptives from PFE (see BioCentury, March 10). GAL also is acquiring a femhrt hormone replacement therapy from Pharmacia Corp. (PHA, Peapack, N.J.). PFE is...
08:00 , Mar 10, 2003 |  BC Week In Review  |  Company News

Galen, Pfizer deal

GAL will acquire Estrostep and Loestrin oral contraceptives and a femhrt hormone replacement therapy from PFE for an upfront cash payment of $359 million. The femhrt product is from Pharmacia Corp. (PHA, Peapack, N.J.) which...
08:00 , Mar 6, 2003 |  BC Extra  |  Company News

Galen acquires PFE, PHA women's products

Galen (LSE:GAL; GALN) will acquire Estrostep and Loestrin oral contraceptives and a femhrt hormone replacement therapy from Pfizer (PFE) for an upfront cash payment of $359 million. The femhrt product is from Pharmacia (PHA), which...